WALTHAM, Mass., Dec.  13, 2024  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma ("cSCC") or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death l…

Benzinga

New York

United States

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - Fortress Biotech (NASDAQ:FBIO), Checkpoint Therapeutics (NASDAQ:CKPT)

Ad Fontes Media

Media Bias/Fact Check

(Reuters) -The U.S. Food and Drug Administration has approved Neurocrine Biosciences’ drug to treat a type of genetic disorder, the health regulator’s website showed on Friday. The drug, branded as Crenessity, is to be used together with glucocorticoid, a type of steroid, to control androgen levels in adults and pediatric patients aged 4 years and older with classic congenital adrenal hyperplasia (CAH). The drug is expected to be commercially av…

All Sides

WTVB

Midwest Communications

US FDA approves Neurocrine Biosciences’ genetic disorder drug

The US Food and Drug Administration said on Friday it has approved Checkpoint Therapeutics’ drug Unloxcyt for treatment of a type of cancer on the outer layer of the skin. Approval for the drug, which will be sold under the brand Unloxcyt, is for cutaneous squamous cell carcinoma which can be both locally advanced as well as for when it spreads into other areas of the body, the FDA said. Unloxcyt is part of a class called PD-L1 antibody, in whic…

ARY News

Pakistan

Unloxcyt: US approves skin cancer drug

Checkpoint Therapeutics (CKPT) stock rises as FDA approves Unloxcyt as a treatment for certain patients with cutaneous squamous cell carcinoma. Read more here.

Seeking Alpha

Checkpoint stock on watch after FDA nod (CKPT:NASDAQ)

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, MA, USA I December 13, 2024 I Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not cand…

pipelinereview

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - Pipelinereview

The U.S. Food and Drug Administration (FDA) granted approval on Friday to Checkpoint Therapeutics’ new drug, Unloxcyt, for the treatment of a skin cancer known as cutaneous squamous cell carcinoma (cSCC). This approval includes both locally advanced and metastatic forms of the disease. Unloxcyt, which is classified as a PD-L1 antibody, works by attaching to the PD-L1 protein, allowing the immune system to better target and destroy cancer cells. …

Minute Mirror

FDA approves checkpoint therapeutics’ Unloxcyt skin cancer treatment

Breakthrough FDA approval for UNLOXCYT, first PD-L1 blocking antibody treating advanced skin cancer. Novel therapy targets billion-dollar market with unique dual mechanism.

stocktitan.net

Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market

(Reuters) –     The U.S. Food and Drug Administration has approved Neurocrine Biosciences’ drug to treat a type of genetic disorder, the health regulator’s website showed on Friday.   (Reporting by Sriparna Roy in Bengaluru; Editing by Alan Barona) Brought to you by www.srnnews.com

regionalmedianews.com

US FDA approves Neurocrine Biosciences’ genetic disorder drug - Regional Media News

UNLOXCYT: A New Horizon in the Management of Advanced Cutaneous Squamous Cell Carcinoma' CSIMarket.com ' The recent approval of UNLOXCYT (cosibelimab-ipdl) by the U.S. Food and Drug Administration (FDA) marks a significant advancement in the treatment landscape of advanced cutaneous squamous cell carcinoma (cSCC). This novel therapeutic, distinguished as the first and only FDA-approved anti-PD-L1 treatment specifically indicated for advanced cSC…

csimarket.com

#UNLOXCYT A New Horizon in the Management of Advanced Cutaneous Squamous Cell Carcinoma CSIMark...

The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - Fortress Biotech (NASDAQ:FBIO), Checkpoint Therapeutics (NASDAQ:CKPT)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics